Health Canada approves the first generic semaglutide for weight loss

Health Canada authorized the first generic semaglutide injection for weight loss on June 29, 2026, clearing a product from Toronto-based Apotex that copies Novo Nordisk's Wegovy ^[1][2]. It is the third generic semaglutide approved in Canada, and the first one cleared for chronic weight management rather than type 2 diabetes ^[1][2].

The regulator said the product met its standards for safety, efficacy and quality for generic drugs after what it described as a thorough review of the company's evidence ^[1]. Health Canada also said it is reviewing six other generic semaglutide submissions from different companies and expects more decisions "in the coming weeks and months" ^[1].

What was approved

Health Canada described the drug as a once-weekly treatment for patients 12 years and older, used alongside a reduced-calorie diet and increased physical activity for chronic weight management ^[1]. CBC News reported the same age range ^[2]. Apotex's own announcement describes the indication differently, saying it is for adults with obesity (BMI of 30 kg/m² or higher) or overweight (BMI of 27 kg/m² or higher) with at least one weight-related condition, and to reduce the risk of non-fatal heart attack in adults with established cardiovascular disease and a BMI of 27 kg/m² or higher ^[3]. The sources disagree on this point, and the reason for the difference is not explained in them.

The product's name is also inconsistent across sources: Health Canada's news release and Apotex call it Sevmia, while CBC spells it "Svemia" ^[1][2][3]. Apotex says Sevmia is supplied as a multi-use pre-filled pen delivering 1 mg doses, with 4 mg per pen at a concentration of 1.34 mg/mL ^[3]. It was developed with Orbicular Pharmaceutical Technologies ^[3].

Health Canada noted that generic versions of semaglutide are "complex synthetic products that are pharmaceutically equivalent to the brand name biologic drug," and said its review confirms that differences between the products do not affect safety, efficacy or quality ^[1]. The agency said it will keep monitoring all generic semaglutide products and will act if unexpected safety or effectiveness problems appear ^[1].

The price question

Neither Health Canada nor Apotex disclosed a price for Sevmia ^[1][3]. Health Canada said in its quick facts that in Canada, many generic medicines are 45 to 90 percent cheaper than brand-name versions, and that generic availability is expected to produce potential savings for patients and the health system ^[1]. Whether Sevmia lands in that range is not yet known from these sources, and no launch date was announced. Apotex's own release flags the risk that it may not launch the product "on a timely basis or at all" ^[3].

The Canadian timeline has moved quickly. On April 28, 2026, Health Canada became the first G7 regulator to approve a generic semaglutide ^[1]; CBC identified that product as a generic of Ozempic from India-based Dr. Reddy's Laboratories ^[2]. On May 1, 2026, Health Canada approved an Apotex generic semaglutide for once-weekly treatment of adults with type 2 diabetes ^[1]. Health Canada said its review target for generic submissions is shorter than that of many international regulators ^[1].

Why it matters for patients

For people in the United States, the direct effect is none: these approvals apply only in Canada, and none of the sources describe any US regulatory action, launch plan or pricing change for generic semaglutide. Anyone reading headlines about "generic Wegovy" should note the geography.

What the Canadian decisions do offer is a preview. Semaglutide is a peptide made by chemical synthesis, and copying it well has been an open question. Health Canada's statement that its review confirmed pharmaceutical equivalence and that differences do not affect safety, efficacy or quality is one regulator's public answer to that question ^[1]. With six more submissions in the queue ^[1], Canada will also serve as an early test of whether multiple generic entrants actually push prices down in the 45-to-90 percent range Health Canada cites for generics generally ^[1].

It is worth noting what is still unknown from these sources: the Canadian retail or public-plan price, when Sevmia will actually reach pharmacies, how provincial drug plans will cover it, and whether the label truly extends to adolescents aged 12 and up given the conflicting descriptions ^[1][2][3].

What happens next

Health Canada said decisions on the six remaining generic semaglutide submissions are expected in the coming weeks and months ^[1]. Apotex has not announced a Sevmia launch date ^[3]. Health-care professionals in Canada were pointed to the full product monograph for warnings, precautions and monitoring details ^[3].